What's on this Page
Clobetasol Brand Names
Clobevate | Clobex | Clodan | Cormax | Embeline | Embeline E | Impoyz | Olux | Olux-E | Olux-Olux-E Complete Pack | Temovate | Temovate E
What is Clobetasol
Clobetasol is a topical, synthetic fluorinated corticosteroid.
Clobetasol is used to relieve the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses and psoriasis.
Clobetasol is one of the most potent topical corticosteroids, and is usually recommended for short-term or cyclic therapy only.
Very high potency topical corticosteroids are used as an alternative to systemic therapy for localized conditions.
Long-term use can lead to systemic side effects, including hypothalamic-pituitary-adrenal (HPA) axis suppression.
Clobetasol was first approved by the FDA in 1985.
Indications
- alopecia
- aphthous ulcer
- atopic dermatitis
- contact dermatitis
- discoid lupus erythematosus
- eczema
- erythema multiforme
- exfoliative dermatitis
- granuloma annulare
- hemangioma
- keloids
- lichen planus
- lichen sclerosus
- lichen simplex
- lichen striatus
- necrobiosis lipoidica diabeticorum
- pemphigus
- pityriasis rosea
- psoriasis
- Rhus dermatitis
- sarcoidosis
- urticaria
Side Effects
- acneiform rash
- adrenocortical insufficiency
- alopecia
- cataracts
- contact dermatitis
- Cushing’s syndrome
- erythema
- folliculitis
- glycosuria
- growth inhibition
- headache
- hyperglycemia
- hypertension
- hypertrichosis
- hypothalamic-pituitary-adrenal (HPA) suppression
- impaired wound healing
- increased intracranial pressure
- infection
- maculopapular rash
- miliaria
- ocular hypertension
- ocular irritation
- papilledema
- pruritus
- pseudotumor cerebri
- retinopathy
- skin atrophy
- skin hypopigmentation
- skin irritation
- skin ulcer
- striae
- telangiectasia
- tolerance
- vesicular rash
- visual impairment
- withdrawal
- xerosis
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- acne rosacea
- acne vulgaris
- breast-feeding
- cataracts
- children
- corticosteroid hypersensitivity
- Cushing’s syndrome
- diabetes mellitus
- fungal infection
- geriatric
- glaucoma
- growth inhibition
- hepatic disease
- herpes infection
- hypothalamic-pituitary-adrenal (HPA) suppression
- increased intracranial pressure
- infants
- infection
- measles
- neonates
- occlusive dressing
- ocular exposure
- perioral dermatitis
- peripheral vascular disease
- pregnancy
- skin abrasion
- skin atrophy
- tobacco smoking
- varicella
- viral infection
Interactions
- Deferasirox
- Metyrapone
Deferasirox: (Moderate) Because gastric ulceration and GI bleeding have been reported in patients taking deferasirox, use caution when coadministering with other drugs known to increase the risk of peptic ulcers or gastric hemorrhage including corticosteroids.
Metyrapone: (Major) Medications which affect pituitary or adrenocortical function, including all corticosteroid therapy, should be discontinued prior to and during testing with metyrapone.
Patients taking inadvertent doses of corticosteroids on the test day may exhibit abnormally high basal plasma cortisol levels and a decreased response to the test. Although systemic absorption of topical corticosteroids is minimal, temporary discontinuation of these products should be considered if possible to reduce the potential for interference with the test results.
